Page 228 - 2022_01-Haematologica-web

L. Raman et al.
21. Adalsteinsson VA, Ha G, Freeman SS, et al. Scalable whole-exome sequencing of cell- free DNA reveals high concordance with metastatic tumors. Nat Commun. 2017; 8(1):1324.
22. Liaw A, Wiener M. Classification and Regression by random Forest. R News. 2002;2(3):18-22.
23. Mermel CH, Schumacher SE, Hill B, Meyerson ML, Beroukhim R, Getz G. GIS- TIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers. Genome Biol. 2011;12(4):R41.
24. Van der Linden M, Raman L, Vander Trappen A, et al. Detection of copy number alterations by shallow whole-genome sequencing of formalin-fixed, paraffin- embedded tumor tissue. Arch Pathol Lab Med. 2020;144(8):974-981.
25. Mathas S, Hartmann S, Küppers R. Hodgkin lymphoma: Pathology and biolo- gy. Semin Hematol. 2016;53(3):139-147.
26. Ward JH Jr. Hierarchical grouping to opti- mize an objective function. J Am Stat Assoc. 1963;58(301):236-244.
27. Rosenwald A, Wright G, Leroy K, et al. Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma. J Exp Med. 2003;198(6):851-862.
28. Eberle FC, Rodriguez-Canales J, Wei L, et al. Methylation profiling of mediastinal gray zone lymphoma reveals a distinctive signature with elements shared by classical Hodgkin’s lymphoma and primary medi- astinal large B-cell lymphoma.
Haematologica. 2011;96(4):558-566.
29. Alizadeh AA, Eisen MB, Davis RE, et al. Distinct types of diffuse large B-cell lym- phoma identified by gene expression profil-
ing. Nature. 2000;403(6769):503-511.
30. Joos S, Menz CK, Wrobel G, et al. Classical Hodgkin lymphoma is characterized by recurrent copy number gains of the short arm of chromosome 2. Blood. 2002;99(4):
1381-1387.
31. Houldsworth J, Mathew S, Rao PH, et al.
REL proto-oncogene is frequently ampli- fied in extranodal diffuse large cell lym- phoma. Blood. 1996;87(1):25-29.
32. Green MR, Monti S, Rodig SJ, et al. Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lym- phoma. Blood. 2010;116(17):3268-3277.
33. Lenz G, Wright GW, Emre NCT, et al. Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic path- ways. Proc Natl Acad Sci U S A. 2008;105(36):13520-13525.
34. Pasqualucci L, Trifonov V, Fabbri G, et al. Analysis of the coding genome of diffuse large B-cell lymphoma. Nat Genet. 2011;43(9):830-837.
35. Kober-Hasslacher M, Schmidt-Supprian M. The unsolved puzzle of c-Rel in B cell lym- phoma. Cancers. 2019;11(7):941.
36. Castillo JJ, Reagan JL. Plasmablastic lym- phoma: a systematic review. Scientific World Journal. 2011;11:687-696.
37. Iacoboni G, Zucca E, Ghielmini M, Stathis A. Methodology of clinical trials evaluating
the incorporation of new drugs in the first- line treatment of patients with diffuse large B-cell lymphoma (DLBCL): a critical review. Ann Oncol. 2018;29(5):1120-1129.
38. Scherer F, Kurtz DM, Newman AM, et al. Distinct biological subtypes and patterns of genome evolution in lymphoma revealed by circulating tumor DNA. Sci Transl Med. 2016;8(364):364ra155.
39. Kurtz DM, Scherer F, Jin MC, et al. Circulating tumor DNA measurements as early outcome predictors in diffuse large B- cell lymphoma. J Clin Oncol. 2018;36(28): 2845-2853.
40. Mouliere F, Mair R, Chandrananda D, et al. Detection of cell-free DNA fragmentation and copy number alterations in cere- brospinal fluid from glioma patients. EMBO Mol Med. 2018;10(12):e9323.
41. Cristiano S, Leal A, Phallen J, et al. Genome-wide cell-free DNA fragmenta- tion in patients with cancer. Nature. 2019;570(7761):385-389.
42. Deeren D, Van Der Linden M, Dedeurwaerdere F, et al. Circulating cell- free DNA for response evaluation of intravascular lymphoma. Ann Hematol. 2019;98(8):2021-2023.
43.Rinaldi A, Kwee I, Poretti G, et al. Comparative genome-wide profiling of post-transplant lymphoproliferative disor- ders and diffuse large B-cell lymphomas. Br J Haematol. 2006;134(1):27-36.
44. Morscio J, Dierickx D, Tousseyn T. Molecular pathogenesis of B-cell posttrans- plant lymphoproliferative disorder: what do we know so far? Clin Dev Immunol. 2013;2013:150835.
220
haematologica | 2022; 107(1)